DavidJPolinger-HymanMD

PubMed

• Magnetic resonance imaging-derived relative cerebral blood volume characteristics in a case of pathologically confirmed neurocysticercosis: illustrative case.
  Botros, N., Beck, R., Kleefisch, C., Mrachek, E., Connelly, J., Schmainda, K., Polinger-Hyman, D., Krucoff, M.> ;Journal of Neurosurgery. Case Lessons. 2023 Dec 18
• 10 citations
  Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
  Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Li Ann Wong, Alison M. Schram, Hele...> ;NPJ Breast Cancer. 2021 Apr 16
• 7 citations
  Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
  Shivaani Kummar, Jordan Berlin, Leo Mascarenhas, Cornelis M. van Tilburg, Birgit Geoerger, Ulrik Lassen, Russell J. Schilder, Brian Turpin, Shivani Nanda, Karen Keatin...> ;Current Problems in Cancer. 2021 Apr 2
• 22 citations
  Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.
  Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine Kargus, Lynette ...> ;Clinical Cancer Research. 2021 Mar 16
• 17 citations
  Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
  Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Phil...> ;Clinical Cancer Research. 2021 Jan 15
• 11 citations
  Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers
  J. Wu, Dazhi Liu, Michael Offin, Cecilia Lezcano, Jean Torrisi, S. Brownstein, David M. Hyman, Mrinal M. Gounder, W. Abida, Alexander Drilon, James J. Harding, Ryan J....> ;Investigational New Drugs. 2021 Jan 3
• 26 citations
  TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
  Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristo...> ;Cancer Discovery. 2021 Jan 1
• 27 citations
  Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation.
  Pier Selenica, Niamh Conlon, Carlene Gonzalez, Denise Frosina, Achim A. Jungbluth, Regina G. H. Beets-Tan, Mamta Rao, Yanming Zhang, Ryma Benayed, Marc Ladanyi, David ...> ;The American Journal of Surgical Pathology. 2021 Jan 1
• 4 citations
  Clinical implications of drug-induced liver injury in early-phase oncology clinical trials.
  Sebastian Mondaca, Dazhi Liu, Jessica Flynn, Sandy Badson, Stefan Hamaway, Mrinal M. Gounder, Danny N. Khalil, Alexander Drilon, Bob T. Li, Komal Jhaveri, Alison M. Sc...> ;Cancer. 2020 Nov 15
• 16 citations
  Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis.
  Antoine Italiano, Shivani Nanda, Andrew Briggs, Jesús García-Foncillas, Ulrik Lassen, Gilles Vassal, Shivaani Kummar, Cornelis M. van Tilburg, David S. Hong, Theodore ...> ;Cancers. 2020 Nov 4
• 288 citations
  Cancer therapy shapes the fitness landscape of clonal hematopoiesis
  Kelly L. Bolton, Ryan Ptashkin, Teng Gao, Lior Z. Braunstein, Sean M. Devlin, Daniel Kelly, Minal Patel, Antonin Berthon, Aijazuddin Syed, Mariko Yabe, Catherine C. Co...> ;Nature Genetics. 2020 Oct 26
• 30 citations
  Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.
  Ankush Bhatia, Vaios Hatzoglou, Gary A. Ulaner, Raajit K. Rampal, David M. Hyman, Omar Abdel-Wahab, Benjamin H. Durham, Ahmet Dogan, Neval Ozkaya, Mariko Yabe, Kseniya...> ;Neuro-Oncology. 2020 Jul 7
• 31 citations
  Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT
  Gary A. Ulaner, Jorge A. Carrasquillo, Christopher C. Riedl, Randy Yeh, Vaios Hatzoglou, Dara S. Ross, Komal Jhaveri, Sarat Chandarlapaty, David M. Hyman, Brian M. Zeg...> ;Radiology. 2020 Jun 9
• 6 citations
  MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants.
  Jasmine H. Francis, Eli L. Diamond, Ping Chi, Korey Jaben, David M. Hyman, David H. Abramson> ;Ocular Oncology and Pathology. 2020 May 1
• 18 citations
  Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.
  Dara S. Ross, Bo Liu, Alison M. Schram, Pedram Razavi, S.M. Lagana, Yanming Zhang, Maurizio Scaltriti, Jacqueline Bromberg, M. Ladanyi, David M. Hyman, A. Drilon, Ahme...> ;Annals of Oncology. 2020 Aug 1
• 50 citations
  Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
  Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen Ambrose, Jack Ashton, Alan Barnicle, Des D....> ;Clinical Cancer Research. 2020 Apr 20
• 52 citations
  Genomic Landscape of Uterine Sarcomas Defined through Prospective Clinical Sequencing
  Martee L. Hensley, Shweta S. Chavan, David B. Solit, Rajmohan Murali, Robert A. Soslow, Sarah Chiang, Achim A. Jungbluth, Chaitanya Bandlamudi, Preethi Srinivasan, Wil...> ;Clinical Cancer Research. 2020 Apr 16
• 17 citations
  Toward a More Precise Future for Oncology.
  Yonina R. Murciano-Goroff, Barry S. Taylor, David M. Hyman, Alison M. Schram> ;Cancer Cell. 2020 Apr 13
• 490 citations
  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
  David S. Hong, Steven G. DuBois, Shivaani Kummar, Anna F. Farago, Catherine M. Albert, Kristoffer Staal Rohrberg, Cornelis M. van Tilburg, Ramamoorthy Nagasubramanian,...> ;The Lancet. Oncology. 2020 Apr 1
• 95 citations
  TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
  Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Albe...> ;Clinical Cancer Research. 2020 Apr 1
• 224 citations
  Small molecules, big impact: 20 years of targeted therapy in oncology.
  Philippe L. Bedard, David M. Hyman, Matthew S. Davids, Lillian L. Siu> ;Lancet. 2020 Mar 28
• 121 citations
  HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
  Bob T. Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai-Yan Tu, Mackenzie L. Myers, Chongrui Xu, Marissa Mattar, Inn...> ;Cancer Discovery. 2020 Mar 25
• 34 citations
  Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
  Maria M. Rubinstein, David M. Hyman, Imogen Caird, Helen Won, Krysten Soldan, Kenneth Seier, Alexia Iasonos, William P. Tew, Roisin E. O'Cearbhaill, Rachel N. Grisham,...> ;Cancer. 2020 Mar 15
• 78 citations
  Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
  Vivek Subbiah, Igor Puzanov, Jean-Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje, Juergen Wolf, José Baselga, Funda Meric-Bernstam, Jason Roszik, Eli L. Diamond, ...> ;Cancer Discovery. 2020 Feb 6
• 69 citations
  Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
  Lillian M. Smyth, Sarina Anne Piha-Paul, Helen Won, Alison M. Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I. Shapiro, Dejan Juric, Ingrid A. Mayer, Carlos...> ;Cancer Discovery. 2020 Feb 1
• Join now to see all